{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:34:19Z","timestamp":1778751259095,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study examined the ex-vivo occupancy by KMD-3213 of \u03b11-adrenoceptors in the prostate and other tissues of rats in terms of tissue selectivity and duration of occupancy in relation to plasma concentration. Oral administration of KMD-3213 (0.2\u201320.2\u03bcmol kg\u22121, 0.5 h) dose-dependently decreased [3H]prazosin binding sites (Bmax) in the prostate (42\u201374%) and submaxillary gland (54\u201388%) compared with the control value. In contrast, there was only a slight change in the Bmax values in the spleen and cerebral cortex of KMD-3213-treatedrats. The \u03b11-adrenoceptor occupancy in the prostate and submaxillary gland was increased, with plasma free concentration of KMD-3213 at 0.5 h after oral administration of KMD-3213 (0.6\u201320.2 \u03bc mol kg\u22121). The receptor occupancy in these tissues was much greater than that in the spleen, heart or cerebral cortex. After oral administration of KMD-3213 (6.1 \u03bc mol kg\u22121), the \u03b11-adrenoceptor occupancy in the prostate and submaxillary gland occurred rapidly, in parallel with the rise in the plasma concentration of the drug, and it lasted for at least 24 h, despite a remarkable decrease in the plasma concentration. It is concluded that KMD-3213 may produce fairly selective and sustained occupancy of \u03b11-adrenoceptors in the prostate, a target organ for treatment of bladder outlet obstruction in patients with benign prostatic hyperplasia.<\/jats:p>","DOI":"10.1211\/002235702760089108","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T20:14:04Z","timestamp":1034367244000},"page":"975-982","source":"Crossref","is-referenced-by-count":13,"title":["Selective and sustained occupancy of prostatic \u03b11-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats"],"prefix":"10.1093","volume":"54","author":[{"given":"T","family":"Okura","sequence":"first","affiliation":[{"name":"Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka , 52-1 Yada, Shizuoka 422-8526,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka , 52-1 Yada, Shizuoka 422-8526,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Abe","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Research, Research and Development, Kissei Pharmaceutical Co., Ltd , 19-48 Yoshino, Matsumoto, Nagano 399-8710,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka , 52-1 Yada, Shizuoka 422-8526,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,7,1]]},"reference":[{"key":"2024103109381813200_cit1","first-page":"81","article-title":"KMD-3213, a uroselective and long-acting a1a-adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit2","first-page":"612","article-title":"In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency","volume":"272","author":"Beauchamp","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit3","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1073\/pnas.94.21.11589","article-title":"Decreased blood pressure response in mice deficient of the a1b-adrenergicreceptor","volume":"94","author":"Cavalli","year":"1997","journal-title":"Proc. Natl Acad. Sci."},{"key":"2024103109381813200_cit4","first-page":"209","article-title":"RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy) ethyl]-5-chloro-a,a-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective a1A-adrenoceptor antagonist, displays low af nity for functional a1-adrenoceptors in human prostate: implications for adrenoceptor classification","volume":"49","author":"Ford","year":"1996","journal-title":"Mol. Pharmacol"},{"key":"2024103109381813200_cit5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0014-2999(88)90819-9","article-title":"5-Methyl-urapidil discriminates between subtypes of the a1-adrenoceptor","volume":"151","author":"Gross","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"2024103109381813200_cit6","first-page":"505","article-title":"Heterogeneity of a1-adrenergic receptors revealed by chlorethylclonidine","volume":"32","author":"Han","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"2024103109381813200_cit7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1994.tb17053.x","article-title":"Pharmacological evidence of distinct a1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery","volume":"113","author":"Hatano","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"2024103109381813200_cit8","first-page":"267","article-title":"International Union of Pharmacology. X. Recommendation for nomenclature of a1 adrenoceptors: consensus update","volume":"47","author":"Hieble","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"2024103109381813200_cit9","first-page":"199","article-title":"Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists","volume-title":"Goodman and Gillman's the pharmacological basis of therapeutics","author":"Hoffman","year":"1996","edition":"9th"},{"key":"2024103109381813200_cit10","first-page":"102","article-title":"Kinetics of receptor occupation and anticonvulsive effects of diazepam in rats","volume":"13","author":"Igari","year":"1985","journal-title":"Drug Metab. Dispos."},{"key":"2024103109381813200_cit11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pros.2990220404","article-title":"The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle","volume":"22","author":"Lepor","year":"1993","journal-title":"Prostate"},{"key":"2024103109381813200_cit12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"2024103109381813200_cit13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1476-5381.1995.tb15001.x","article-title":"Noradrenaline contractions of human prostate mediated by a1A- (a1C-) adrenoceptor subtype","volume":"115","author":"Marshall","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"2024103109381813200_cit14","first-page":"883","article-title":"Identification of a single a1-adrenoceptor corresponding to the a1A-subtype in rat submaxillary gland. Br","volume":"98","author":"Michel","year":"1989","journal-title":"J. Pharmacol."},{"key":"2024103109381813200_cit15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00171338","article-title":"a1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy","volume":"348","author":"Michel","year":"1993","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2024103109381813200_cit16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00169183","article-title":"Classification of a1-adrenoceptor subtypes","volume":"352","author":"Michel","year":"1995","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2024103109381813200_cit17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(97)01009-1","article-title":"KMD-3213, a novel a1A-adrenoceptor antagonist, potently inhibits the functional a1-adrenoceptor in human prostate","volume":"331","author":"Moriyama","year":"1997","journal-title":"Eur. J. Pharmacol"},{"key":"2024103109381813200_cit18","first-page":"23","article-title":"Functional classification of vascular a-adrenoceptors","volume":"6","author":"Muramatsu","year":"1995","journal-title":"Pharmacol Commun."},{"key":"2024103109381813200_cit19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjp.0702489","article-title":"Pharmacological analysis of the novel, selective a1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand","volume":"127","author":"Murata","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"2024103109381813200_cit20","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0024-3205(98)00495-0","article-title":"Ex vivo occupancy by tamsulosin of a1-adrenoceptors in rat tissues in relation to the plasma concentration","volume":"63","author":"Ohkura","year":"1998","journal-title":"Life Sci."},{"key":"2024103109381813200_cit21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(17)35544-1","article-title":"Identification, quantification, and localization of mRNA for three distinct a1 adrenergic receptor subtypes in human prostate","volume":"150","author":"Price","year":"1993","journal-title":"J. Urol."},{"key":"2024103109381813200_cit22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0003-2697(67)90297-7","article-title":"Graphic method for the determination and presentation of binding parameters in a complex system","volume":"20","author":"Rosenthal","year":"1967","journal-title":"Anal. Biochem."},{"key":"2024103109381813200_cit23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00005392-200101000-00010","article-title":"a -Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it","volume":"165","author":"Rossi","year":"2001","journal-title":"J. Urol."},{"key":"2024103109381813200_cit24","first-page":"250","article-title":"KMD-3213, a novel, potent, a1a-adrenoceptor-selective antagonist: characterization using recombinant human a1-adrenoceptors and native tissues","volume":"48","author":"Shibata","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"2024103109381813200_cit25","first-page":"526","article-title":"Identification and structural characterization of a1-adrenergic receptor subtypes","volume":"37","author":"Terman","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"2024103109381813200_cit26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0014-2999(93)90527-O","article-title":"Characterization of a1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man","volume":"249","author":"Testa","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"2024103109381813200_cit27","first-page":"176","article-title":"Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment","volume":"215","author":"Yamada","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit28","first-page":"326","article-title":"Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy","volume":"242","author":"Yamada","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit29","first-page":"239","article-title":"Integration of pharmacokinetics and pharmacodynamicsin drug development- in vivo receptor occupancy by calcium antagonist and angiotensin II receptor antagonist","volume":"4","author":"Yamada","year":"1998","journal-title":"Curr. Top. Pharmacol."},{"key":"2024103109381813200_cit30","first-page":"1575","article-title":"In vivo measurement by [3H]tamsulosin of a1 adrenoceptors in rat tissues in relation to the pharmacokinetics","volume":"289","author":"Yamada","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit31","first-page":"160","article-title":"In vivo demonstration of a1A adrenoceptor subtype selectivity of KMD-3213 in rat tissues","volume":"296","author":"Yamada","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109381813200_cit32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(96)00589-4","article-title":"Effect of KMD-3213, an a1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta","volume":"315","author":"Yamagishi","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"2024103109381813200_cit33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1254\/jjp.62.403","article-title":"a1-Adrenoceptor subtype in the rat prostate is preferentially the a1A type","volume":"62","author":"Yazawa","year":"1993","journal-title":"Jpn. J. Pharmacol"},{"key":"2024103109381813200_cit34","first-page":"23","article-title":"Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays","volume":"279","author":"Zernig","year":"1996","journal-title":"J. Pharmacol Exp. Ther."},{"key":"2024103109381813200_cit35","first-page":"829","article-title":"a1-Adrenoceptor subtype mediating inotropic responses in rat heart","volume":"291","author":"Zhang","year":"1999","journal-title":"J. Pharmacol Exp. Ther."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F002235702760089108","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/54\/7\/975\/60258959\/002235702760089108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/54\/7\/975\/60258959\/002235702760089108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:05:02Z","timestamp":1730369102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/54\/7\/975\/6151851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2002,7,1]]},"published-print":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1211\/002235702760089108","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,7]]},"published":{"date-parts":[[2002,7,1]]}}}